RIGScan CR-49 imaging agent data

Preliminary results from a Phase II trial with 46 evaluable patients (of 52) and a Phase III trial with 110 evaluable patients (of 151) showed that the CR-49 imaging agent found 20 and 21 percent additional cancer during surgery, respectively, compared to surgery alone.

Surgical management changes as a result of this information included removal of more tumor, abandoning surgery because disease was too extensive, or removing more tissue at the edges of the tumor. Results were presented at the Society of Surgical Oncology's Cancer Symposium in Atlanta, Ga. ...